Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor

Molecular Cancer Therapeutics

Volumn 8, Issue 8, 2009, Pages 2172-2182

  Rink, Lori ^a   Skorobogatko, Yuliya ^a   Kossenkov, Andrew V ^a,g   Belinsky, Martin G ^a   Pajak, Thomas ^b   Heinrich, Michael C ^c   Blanke, Charles D ^d   Von Mehren, Margaret ^a   Ochs, Michael F ^e   Eisenberg, Burton ^f   Godwin, Andrew K ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^g WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; ZINC FINGER PROTEIN;

ADULT; AGED; ARTICLE; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; KRAB ZNF GENE; KRUPPEL ASSOCIATED BOX DOMAIN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PIPERAZINES; PYRIMIDINES; ZINC FINGERS;

EID: 68849122493     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0193     Document Type: Article

References (39)

1. Corless CL, Heinrich MC. Molecular pathobiology of gastrointestinal stromal sarcomas. Ann Rev Pathol 2008;3:557-86.
2. El-Rifai W, Sarlomo-Rikala M, Andersson LC, Knuutila S, Miettinen M. DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. Cancer Res 2000;60:3899-903.
3. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Archiv Pathol Lab Med 2006;130:1466-78.
4. Tworek JA, Appelman HD, Singleton TP, Greenson JK. Stromal tumors of the jejunum and ileum. Mod Pathol 1997;10:200-9.
5. Miettinen M, Kopczynski J, Makhlouf HR, et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. Am J Surg Pathol 2003;27:625-41.
6. Tworek JA, Goldblum JR, Weiss SW, Greenson JK, Appelman HD. Stromal tumors of the anorectum: a clinicopathologic study of 22 cases. Am J Surg Pathol 1999;23:946-54.
7. Miettinen M, Monihan JM, Sarlomo-Rikala M, et al. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol 1999;23:1109-18.
8. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004;22:3813-25.
9. Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983;7:507-19.
10. Graadt van Roggen JF, van Velthuysen ML, Hogendoorn PC. The histopathological differential diagnosis of gastrointestinal stromal tumours. J Clin Pathol 2001;54:96-102.
11. Heinrich MC, Corless CL. Gastric GIstromal tumors (GISTs): the role of surgery in the era of targeted therapy. J Surg Oncol 2005;90:195-207, discussion.
12. Subramanian S, West RB, Corless CL, et al. Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. Oncogene 2004;23:7780-90.
13. Tarn C, Merkel E, Canutescu AA, et al. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling. Clin Cancer Res 2005;11:3668-77.
14. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42:1093-103.
15. Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 2004;11:465-75.
16. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-8.
17. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
18. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-34.
19. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2002;38 Suppl 5:S60-5.
20. Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005;41:1751-7.
21. Prenen H, Cools J, Mentens N, et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 2006;12:2622-7.
22. Weisberg E, Wright RD, Jiang J, et al. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Gastroenterology 2006;131:1734-42.
23. Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006;66:473-81.
24. Bauer S, Yu LK, Demetri GD, Fletcher JA. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 2006;66:9153-61.
25. Godwin AK, Vanderveer L, Schultz DC, et al. A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1. Am J Hum Genet 1994;55:666-77.
26. Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002;160:1567-72.
27. Grant JD, Somers LA, Zhang Y, Manion FJ, Bidaut G, Ochs MF. FGDP: functional genomics data pipeline for automated, multiple microarray data analyses. Bioinformatics (Oxford, England) 2004;20:282-3.
28. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
29. Saeed AI, Sharov V, White J, et al. TM4: a free, open-source system for microarray data management and analysis. BioTechniques 2003;34:374-8.
30. Chen X, Arciero CA, Wang C, Broccoli D, Godwin AK. BRCC36 is essential for ionizing radiation-induced BRCA1 phosphorylation and nuclear foci formation. Cancer Res 2006;66:5039-46.
31. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006;24:4764-74.
32. Hamilton AT, Huntley S, Tran-Gyamfi M, Baggott DM, Gordon L, Stubbs L. Evolutionary expansion and divergence in the ZNF91 subfamily of primate-specific zinc finger genes. Genome Res 2006;16:584-94.
33. Mark C, Abrink M, Hellman L. Comparative analysis of KRAB zinc finger proteins in rodents and man: evidence for several evolutionarily distinct subfamilies of KRAB zinc finger genes. DNA Cell Biol 1999;18:381-96.
34. Lovering R, Trowsdale J.Agene encoding 22 highly related zinc fingers is expressed in lymphoid cell lines. Nucleic Acids Res 1991;19:2921-8.
35. Unoki M, Okutsu J, Nakamura Y. Identification of a novel human gene, ZFP91, involved in acute myelogenous leukemia. Int J Oncol 2003;22:1217-23.
36. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science (New York, NY) 2006;314:268-74.
37. Chung YJ, Kim TM, Kim DW, et al. Gene expression signatures associated with the resistance to imatinib. Leukemia 2006;20:1542-50.
38. van Wijnen AJ, Massung RF, Stein JL, Stein GS. Human H1 histone gene promoter CCAAT box binding protein HiNF-B is a mosaic factor. Biochemistry 1988;27:6534-41.
39. Vogel MJ, Guelen L, de Wit E, et al. Human heterochromatin proteins form large domains containing KRAB-ZNF genes. Genome Res 2006;16:1493-504.